

CLAIM AMENDMENTS:

1. (Previously Presented) A composition comprising as the sole pharmacologically active components:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;
- (b) a source of salicylic acid a physiologically acceptable derivative thereof;
- (c) vitamin C and, optionally, one or more of:
- (d) a physiologically acceptable source of assimilable manganese;
- (e) a physiologically acceptable source of assimilable iron;
- (f) a physiologically acceptable source of assimilable sulphur; and
- (g) a physiologically acceptable source of assimilable zinc.

2-20. (Cancelled)

21. (Previously Presented) The composition according to Claim 1 comprising as the sole pharmacologically active components:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;

- (b) salicylic acid or an alkali or alkaline earth metal salt thereof; and
- (c) vitamin C.

22. (Previously Presented) The composition according to Claim 1, containing (e) a physiologically acceptable source of assimilable iron and (f) a physiologically acceptable source of assimilable sulphur.

23. (Previously Presented) The composition according to Claim 1, containing a physiologically acceptable source of assimilable zinc.

24. (Previously Presented) The composition according to Claim 1, wherein the said metals are present in the form of salts with organic or inorganic acids.

25. (Previously Presented) The composition according to Claim 24, wherein the salts are the same or different and are selected from the group consisting of orotates, aspartates, gluconates, tartrates, citrates, lactates and acetates.

26. (Previously Presented) The composition according to Claim 25, wherein the copper salt is selected from the group consisting of copper gluconate and copper orotate and the manganese salt, if present, is selected from the group consisting of manganese gluconate and manganese orotate.

27. (Previously Presented) The composition according to Claim 24, wherein the salts are the same or different and are selected from the group consisting of chlorides, bromides, iodides, phosphates and sulphates.

28. (Previously Presented) The composition according to Claim 1, wherein component (b) is sodium salicylate.

29. (Previously Presented) A composition comprising:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;
- (b) salicylic acid or an alkali or alkaline earth metal salt thereof;
- (c) vitamin C; and
- (d) a physiologically acceptable source of assimilable manganese.

30. (Previously Presented) The composition according to Claim 29, containing (e) a physiologically acceptable source of assimilable iron and (f) a physiologically acceptable source of assimilable sulphur.

31. (Previously Presented) The composition according to Claim 29, containing a physiologically acceptable source of assimilable zinc.

32. (Previously Presented) The composition according to Claim 29, wherein the said metals are present in the form of salts with organic or inorganic acids.

33 (Previously Presented) The composition according to claim 32, wherein the salts are the same or different and are selected from the group consisting of orotates, aspartates, gluconates, tartrates, citrates, lactates and acetates.

34. (Previously Presented) A composition according to Claim 33, wherein the copper salt is selected from the group consisting of copper gluconate and copper orotate and the manganese salt, if present, is selected from the group consisting of manganese gluconate and manganese orotate.

35. (Previously Presented) The composition according to claim 32, wherein the salts are the same or different and are selected from the group consisting of chlorides, bromides, iodides, phosphates and sulphates.

36. (Previously Presented) The composition according to Claim 29, wherein component (b) is sodium salicylate.

37. (Previously Presented) A composition comprising:
15 to 60 parts by weight copper gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable copper other than copper gluconate is used;
300 to 600 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used; and
200 to 1000 parts by weight vitamin C,
the parts by weight referred to being based on the total weight of these ingredients in the composition.

Q
CON

38. (Previously Presented) The composition according to Claim 37 comprising:

15 to 40 parts by weight copper gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable copper other than copper gluconate is used;

300 to 400 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used; and

300 to 500 parts by weight vitamin C.

39. (Previously Presented) The composition according to Claim 37, further comprising 15 to 60 parts by weight manganese gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable manganese other than manganese gluconate is used.

40. (Previously Presented) The composition according to Claim 37, further comprising 15 to 60 parts by weight iron gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable iron other than iron gluconate is used, and 15 to 60 parts by weight of sulphur.

41. (Previously Presented) The composition according to Claim 37, further comprising 15 to 60 parts by weight zinc gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable zinc other than zinc gluconate is used.

42. (Previously Presented) The composition according to Claim 37, comprising:

- (a) 15 to 40 parts by weight copper gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable copper other than copper gluconate is used;
- (b) 350 parts by weight sodium salicylate, or equivalent amount of active ingredient when salicylic acid or another alkali or alkaline earth metal salt thereof other than sodium salicylate is used; and
- (c) 400 parts by weight vitamin C.

43. (Previously Presented) The composition according to Claim 42, further comprising 15 to 40 parts by weight manganese gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable manganese other than manganese gluconate is used.

44. (Previously Presented) The composition according to Claim 42, further comprising 15 to 40 parts by weight iron gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable iron other than iron gluconate is used, and 15 to 40 parts by weight of sulphur.

45. (Previously Presented) The composition according to Claim 42, further comprising 15 to 40 parts by weight zinc gluconate, or equivalent amount of active ingredient when a physiologically acceptable source of assimilable zinc other than zinc gluconate is used.

46. (Previously Presented) A composition comprising as the sole pharmacologically active components:

(a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;

(b) salicylic acid or an alkali or alkaline earth metal salt thereof;

(c) vitamin C and, optionally, one or more of:

(d) a physiologically acceptable source of assimilable manganese;

(e) a physiologically acceptable source of assimilable iron;

(f) a physiologically acceptable source of assimilable sulphur; and

(g) a physiologically acceptable source of assimilable zinc,

wherein the composition is in the form of an orally administrable unit dosage form.

47. (Previously Presented) A composition comprising:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;
- (b) salicylic acid or an alkali or alkaline earth metal salt thereof;
- (c) vitamin C; and
- (d) a physiologically acceptable source of assimilable manganese, wherein the composition is in the form of an orally administrable unit dosage form.

48. (Previously Presented) A composition comprising as the sole pharmacologically active components:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;
- (b) salicylic acid or an alkali or alkaline earth metal salt thereof;
- (c) vitamin C and, optionally, one or more of:
- (d) a physiologically acceptable source of assimilable manganese;
- (e) a physiologically acceptable source of assimilable iron;

(f) a physiologically acceptable source of assimilable sulphur; and
(g) a physiologically acceptable source of assimilable zinc,
for use in the treatment of the human or animal body by therapy.

49. (Previously Presented) A composition comprising:
(a) a physiologically acceptable source of assimilable copper other than
a copper salicylate complex;
(b) salicylic acid or an alkali or alkaline earth metal salt thereof;
(c) vitamin C; and
(d) a physiologically acceptable source of assimilable manganese,
for use in the treatment of the human or animal body by therapy.

50. (Previously Presented) A method of treating or preventing
neoplastic disease in a human or animal patient comprising administering to the
patient an anti-neoplastic effective amount of a composition comprising:

(a) a physiologically acceptable source of assimilable copper other than
a copper salicylate complex;
(b) salicylic acid or an alkali or alkaline earth metal salt thereof; and
(c) vitamin C.

51. (Previously Presented) A method of treating or preventing neoplastic disease in a human or animal patient according to Claim 50 further comprising (d) a physiologically acceptable source of assimilable manganese.

52. (Previously Presented) A pharmaceutical product containing a composition comprising as the sole pharmacologically active components:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;
- (b) salicylic acid or an alkali or alkaline earth metal salt thereof;
- (c) vitamin C and, optionally, one or more of:
- (d) a physiologically acceptable source of assimilable manganese;
- (e) a physiologically acceptable source of assimilable iron;
- (f) a physiologically acceptable source of assimilable sulphur

and

- (g) a physiologically acceptable source of assimilable zinc; and

an additional component selected from the group consisting of vitamin C in addition to that in the composition, one or more amino acids and nicotinic acid, as a combined preparation for simultaneous, separate or sequential use in the treatment of a neoplastic disease.



53. (Previously Presented) A pharmaceutical product containing a composition comprising:

- (a) a physiologically acceptable source of assimilable copper other than a copper salicylate complex;
- (b) salicylic acid or an alkali or alkaline earth metal salt thereof;
- (c) vitamin C; and
- (d) a physiologically acceptable source of assimilable manganese, and

an additional component selected from the group consisting of vitamin C in addition to that in the composition, one or more amino acids and nicotinic acid, as a combined preparation for simultaneous, separate or sequential use in the treatment of a neoplastic disease.

Cone

54. (New) The composition according to Claim 1, wherein said sulphur source comprises sublimed sulphur.

55. (New) The composition according to Claim 1, wherein said amino acid comprises proline.

56. (New) The composition according to Claim 1, wherein said source of copper comprises copper orotate, said source of manganese comprises manganese orotate, said source of iron comprises iron orotate, said source of zinc comprises zinc orotate, said source of sulphur comprises sublimed sulphur, and said derivative of salicylic acid comprises sodium salicylate.
